180 Life Sciences Ár/Könyv
Mi az 180 Life Sciences Ár/Könyv?
A Ár/Könyv az 180 Life Sciences Corp. - -91.95
Mi a Ár/Könyv meghatározása?
Az ár-könyv arány aránya a vállalat részvényértéke és az egy részvényre jutó könyv szerinti érték arányát jelenti.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Ár/Könyv a Health Care szektor a NASDAQ-on cégekben a 180 Life Sciences -hoz képest
Mit csinál 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
ár/könyv -hoz hasonló cégek 180 Life Sciences
- Tuscan nak Ár/Könyv -99.44 van
- Ravindra nak Ár/Könyv -94.72 van
- Napier Ventures nak Ár/Könyv -94.14 van
- Masco nak Ár/Könyv -94.03 van
- Ventoux CCM Acquisition nak Ár/Könyv -93.93 van
- EncounterCare Solutions nak Ár/Könyv -92.78 van
- 180 Life Sciences nak Ár/Könyv -91.95 van
- Fortinet Inc nak Ár/Könyv -91.49 van
- DP Eurasia N.V nak Ár/Könyv -91.24 van
- Candy Club nak Ár/Könyv -88.34 van
- Trend Innovations nak Ár/Könyv -88.03 van
- New West Services nak Ár/Könyv -87.83 van
- Largo Physical Vanadium Corp nak Ár/Könyv -87.15 van